Background “The Jewel of Healthful Tranquility” by Khamzan Burugjal highly commends the formulation “Tumriin Talkh-7” for its broad therapeutic spectrum. Traditionally, it has been recognized for its efficacy in managing digestive and hepatic disorders, chronic heat syndromes, and various systemic imbalances. Listed in the Chinese Pharmacopoeia as a classical Tibetan remedy, it is widely utilized in regions such as Tibet, Qinghai, and Sichuan for treating chronic liver conditions. Nevertheless, despite its extensive use in Tibetan Medicine, its clinical application and scientific evaluation within modern Mongolian medical practice remain limited.
Pharmacological studies show that “Tumriin Talkh-7” has hepatoprotective, anti-inflammatory, and antioxidant effects.
It improves lipid metabolism, reduces hepatic fat, and stabilizes endoplasmic reticulum stress in NAFLD models.
In rats, it lowered ALT, AST, TNF-α, SREBP-1c, and caspase-3, while suppressing NLRP3 inflammasome activity and reducing α-SMA and collagen in fibrosis models. Clinical trials have reported improved liver function and lipid profiles in patients with fatty liver diseases, without major adverse effects. Additionally, preliminary evidence suggests potential benefits in managing rheumatoid arthritis and anemia.
These effects suggest potential therapeutic benefits in treating liver injury and hepatic steatosis. Additionally, clinical observations indicate its positive effects in anemia and inflammatory joint conditions. As mentioned above, the similarity of Mongolian traditional medicine’s liver brown phlegm to Western medicine’s cirrhosis suggests that this drug may be a potential and effective treatment for liver injury and should be further studied.